The Texans re-signed Hansen to a one-year contract Monday, Aaron Wilson of KPRC 2 Houston reports. Hansen appeared in 16 regular-season games for the Texans last season, making two starts. He finished ...

Christopher Bell rallied for an overtime win Sunday at Atlanta Motor Speedway, capturing the Ambetter Health 400 for his 10th career NASCAR Cup Series victory. The Joe Gibbs Racing driver had ...

Between the Class 4A and 3A girls state tournaments, 30 high school basketball games will be played in the Tacoma Dome this weekend. The News Tribune will be at all of them, providing game recaps, ...

Firefighters got applauded, Mick Jagger presented the best original song Oscar and John Lithgow was tasked with looking ...

St. Augustine's Adrian Arbelo (138), Luke Ward (165) and Ron Kraus (190), Mainland Regional’s Chase Hoag (175), Lower’s Bryce ...

A: Carl L. Hansen, CEO, explained that AbCellera is building its translational science and clinical development teams to support its programs. The company is hiring and recruiting based on the ...

Chris Pratt, stunning star from Guardians of ... Full List The King’s Music Room playlists highlights special stories behind Charles’ favourite songs ...

its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest ...

Avidity reported its 2025 outlook, including upcoming clinical and regulatory highlights, and recent organization appointments to execute on the full range of strategic initiatives and growth ...

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...

Citi's Wealth Head Hires BofA Executive Into Key Private Bank Post Chris Biotti will join Citi ... as dozens of states legalized the drug in recent years has slowed to a trickle, pressuring ...

today reported financial results for the fourth quarter and full year 2024 and recent business highlights. “Our most recent clinical data for DYNE-101 from the ACHIEVE trial in DM1 patients ...